* Vanda Pharmaceuticals Inc VNDA.OQ reported a quarterly
adjusted loss of 8 cents per share for the quarter ended
December 31, lower than the same quarter last year, when the
company reported EPS of -4 cents. The mean expectation of
three analysts for the quarter was for a loss of 11 cents per
share. Wall Street expected results to range from -14 cents
to -5 cents per share.
* Revenue rose 17.5% to $53.19 million from a year ago;
analysts
expected $52.25 million.
* Vanda Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 8 cents.
* The company reported a quarterly loss of $4.91 million.
* Vanda Pharmaceuticals Inc shares had fallen by 0.8% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Vanda
Pharmaceuticals Inc is $9.25
This summary was machine generated from LSEG data February 13 at
10:01 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2024 -0.11 -0.08 Beat
Sep. 30 2024 -0.16 -0.09 Beat
Jun. 30 2024 -0.21 -0.08 Beat
-0.07